Q4 2015 13F Holders as of 12/31/2015
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
27.9M
-
Number of holders
-
132
-
Total 13F shares, excl. options
-
14.6M
-
Shares change
-
-545K
-
Total reported value, excl. options
-
$483M
-
Value change
-
-$21.9M
-
Put/Call ratio
-
8.12
-
Number of buys
-
66
-
Number of sells
-
-67
-
Price
-
$33.02
Significant Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) as of Q4 2015
163 filings reported holding ENTA - ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share as of Q4 2015.
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) has 132 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14.6M shares
of 27.9M outstanding shares and own 52.52% of the company stock.
Largest 10 shareholders include Apex Capital Management (1.21M shares), BlackRock Fund Advisors (1.15M shares), EAGLE ASSET MANAGEMENT INC (1.1M shares), Krensavage Asset Management, LLC (878K shares), ACADIAN ASSET MANAGEMENT LLC (809K shares), FMR LLC (739K shares), Invesco Ltd. (649K shares), VANGUARD GROUP INC (616K shares), STATE STREET CORP (585K shares), and ORBIMED ADVISORS LLC (504K shares).
This table shows the top 132 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.